A recent study published in the New England Journal of Medicine suggests a new gene editing drug could help lower high cholesterol levels. This small study included 15 people and was designed to test the medication's safety.

Study authors report that preliminary results showed one dose of the medication reduced low-density lipoprotein (LDL) cholesterol and triglycerides by about half. Both LDL cholesterol and triglycerides contribute to heart disease, the leading cause of death for adults in the U.S.

Minimal side effects were reported from the initial treatment. One participant did die six months after the infusion, but researchers do not believe the death was related to the therapy.

Researchers are planning additional clinical trials that will include more participants. The study was a

See Full Page